Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 11, Issue 1 (January 2009) 11, 22–27; 10.1038/aja.2008.23

Molecular markers in prostate cancer. Part II: potential roles in management

Sachin Agrawal, Krishnaji P. Patil and William D. Dunsmuir

Department of Urology, St Peters Hospital, Chertsey KT16 0PZ, UK

Correspondence: Mr Sachin Agrawal, Department of Urology, St. Peters Hospital, Chertsey KT16 0PZ, UK. Fax: +44-19-3272-2640 E-mail: agrawalsachin@hotmail.com

Received 3 October 2008; Accepted 10 October 2008; Published online 1 December 2008

Abstract

Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.

Keywords: genetics, management, molecular, prostate cancer

PDF | 中文摘要 |

 
Browse:  645
 
Copyright 1999-2015    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved